immune system
|
• 20 hours after administration of OVA323-339 peptide, apoptosis, DNA degradation, chromatin condensation, and cell shrinkage occur in the majority of cortical thymocytes
• apoptosis occurs throughout the thymus including the subcapsular and deep cortical areas
• 3 days after administration of peptide the cortical thymus is acellular; however, normal cellularity exists in the medulla
• peptide administration does not effect small number of thymocytes that express only the beta chain transgene Vb8
|
|
• CD4+CD8+TCR cells in thymic cortex are reduced by 55% after administration of OVA 323-339 peptide
|
|
• CD4+ CD8- TCR thymocytes are reduced in absolute numbers after administration of OVA 323-339 peptide
|
hematopoietic system
|
• 20 hours after administration of OVA323-339 peptide, apoptosis, DNA degradation, chromatin condensation, and cell shrinkage occur in the majority of cortical thymocytes
• apoptosis occurs throughout the thymus including the subcapsular and deep cortical areas
• 3 days after administration of peptide the cortical thymus is acellular; however, normal cellularity exists in the medulla
• peptide administration does not effect small number of thymocytes that express only the beta chain transgene Vb8
|
|
• CD4+CD8+TCR cells in thymic cortex are reduced by 55% after administration of OVA 323-339 peptide
|
|
• CD4+ CD8- TCR thymocytes are reduced in absolute numbers after administration of OVA 323-339 peptide
|
endocrine/exocrine glands
|
• 20 hours after administration of OVA323-339 peptide, apoptosis, DNA degradation, chromatin condensation, and cell shrinkage occur in the majority of cortical thymocytes
• apoptosis occurs throughout the thymus including the subcapsular and deep cortical areas
• 3 days after administration of peptide the cortical thymus is acellular; however, normal cellularity exists in the medulla
• peptide administration does not effect small number of thymocytes that express only the beta chain transgene Vb8
|